Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Selectively targeting the dimerization interface of human androgen receptor with small-molecules to treat castration-resistant prostate cancer.

Cancer letters - 28 Nov 2018

Dalal Kush, Ban Fuqiang, Li Huifang, Morin Hélène, Roshan-Moniri Mani, Tam Kevin J, Shepherd Ashley, Sharma Aishwariya, Peacock James, Carlson Michael L, LeBlanc Eric, Perez Carl, Duong Franck, Ong Christopher J, Rennie Paul S, Cherkasov Artem

Abstract excerpt

Prostate cancer (PCa) is a leading cause of death for men in North America. The androgen receptor (AR) - a hormone inducible transcription factor - drives expression of tumor promoting genes and represents an important therapeutic target in PCa. The AR is activated by steroid recruitment to its ligand binding domain (LBD), followed by receptor nuclear translocation and dimerization via the DNA binding domain...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Imidazoles
Share to Prostatic Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Prostatic Neoplasms, Castration-Resistant

Share to Protein Domains

Share to Protein Multimerization

Share to Receptors, Androgen

Share to Small Molecule Libraries

Share to Thiazoles

Source

Identifiers

PMID: 30165195
DOI: 10.1016/j.canlet.2018.08.016

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Selectively targeting the dimerization interface of human androgen receptor with small-molecules to treat castration-resistant prostate cancer.PMID 30165195Read ↗

The Androgen Receptor in Prostate Cancer: Effect of Structure, Ligands and Spliced Variants on TherapySemantic proximity Read ↗

Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor–Chromatin InteractionsSemantic proximity Read ↗

Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor.Semantic proximity Read ↗

N-terminal domain of androgen receptor is a major therapeutic barrier and potential pharmacological target for treating castration resistant prostate cancer: a comprehensive reviewSemantic proximity Read ↗

Targeting Alternative Sites on the Androgen Receptor to Treat Castration-Resistant Prostate CancerSemantic proximity Read ↗

In Silico Discovery of Androgen Receptor Antagonists with Activity in Castration Resistant Prostate CancerSemantic proximity Read ↗

Exploiting Ligand-binding Domain Dimerization for Development of Novel Androgen Receptor InhibitorsSemantic proximity Read ↗

Discovery of a Small-Molecule Inhibitor Targeting the Androgen Receptor N-Terminal Domain for Castration-Resistant Prostate CancerSemantic proximity Read ↗

Androgen receptor antagonists: a patent review (2008-2011).Semantic proximity Read ↗

Discovery of drugs that directly target the intrinsically disordered region of the androgen receptorSemantic proximity Read ↗

Structure of the homodimeric androgen receptor ligand-binding domainSemantic proximity Read ↗

Analyzing the Androgen Receptor Interactome in Prostate Cancer: Implications for Therapeutic InterventionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.